uniQure (NASDAQ:QURE) Hits New 1-Year High Following Analyst Upgrade

Shares of uniQure (NASDAQ:QURE) reached a new 52-week high during trading on Monday after Stifel Nicolaus raised their price target on the stock from $12.00 to $32.00. Stifel Nicolaus currently has a buy rating on the stock. uniQure traded as high as $17.63 and last traded at $17.54, with a volume of 1889446 shares changing hands. The stock had previously closed at $15.40.

Several other brokerages have also issued reports on QURE. StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. Royal Bank of Canada lifted their price target on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a report on Tuesday, December 10th. Cantor Fitzgerald lifted their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $32.13.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.74% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC grew its stake in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the last quarter. Geode Capital Management LLC lifted its holdings in uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares in the last quarter. Finally, RTW Investments LP purchased a new stake in shares of uniQure in the third quarter worth about $49,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

The business’s fifty day moving average price is $7.04 and its 200-day moving average price is $6.38. The stock has a market capitalization of $848.13 million, a PE ratio of -3.36 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities research analysts expect that uniQure will post -3.82 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.